Risk factor
Resilient to price shocks
Profitability factor
Somewhat favourable analyst view
About
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, neutral on EV/
Target Price
The average target price of BIOCON.NS is 440 and suggests 20% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in
Buy
Sell